Protocol for a phase IV, open-label feasibility study investigating non-invasive markers of hepatic fibrosis in people living with HIV-1 and non-alcoholic fatty liver disease randomised to receiving optimised background therapy (OBT) plus maraviroc or OBT alone

INTRODUCTION: At least 30% of people living with HIV (PLWH) infection have non-alcoholic fatty liver disease (NAFLD), which has now become a leading cause of hepatic fibrosis and cirrhosis. Management is based largely on lifestyle modifications, which are difficult to achieve, and therapeutic option...

Descripción completa

Detalles Bibliográficos
Autores principales: Bradshaw, Daniel, Gilleece, Yvonne, Verma, Sumita, Abramowicz, Iga, Bremner, Stephen, Perry, Nicky
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
HIV/AIDS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342479/
https://www.ncbi.nlm.nih.gov/pubmed/32636281
http://dx.doi.org/10.1136/bmjopen-2019-035596

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342479/
https://www.ncbi.nlm.nih.gov/pubmed/32636281
http://dx.doi.org/10.1136/bmjopen-2019-035596

Ejemplares similares